It's hard to call the current state of the med-tech world healthy, but
some companies are definitely starting to do better. Prominent among
them is Stryker (NYSE:SYK),
which seems to be past its problems in joint reconstruction and back to
building for the future. While I have hopes for the company's ongoing
cost reduction initiatives and its plans for further M&A, I wouldn't
ignore the challenges facing the U.S. orthopedics market. On balance,
absent a new major growth driver, I think Stryker is more or less fairly
valued today, albeit still a high-quality option in the healthcare
space.
Please read the full article here:
http://www.investopedia.com/stock-analysis/071913/stryker-seems-back-track-syk-jnj-cov.aspx
No comments:
Post a Comment